Phenibutum

Фенибут Drug photo

The description is actual on 12.09.2014

  • Latin name: Phenibut
  • ATH code: N05BX
  • Active ingredient: Aminophenyl-butyric acid (Acidum aminophenylbutyricum)
  • Producer: JSC Organika, LLC OZON, CJSC Obninsk Chemical and Pharmaceutical Company, Federal State Unitary Enterprise Moscow Endocrine Plant Russian Federation; JSC Olainfarm, Latvia

Structure

MNN: γ-amino-β-fenilmaslyany acid hydrochloride (Gamma-amino-beta-phenylbutirate hydrochloridum).

One tablet of Phenibutum contains 0,25 g of Phenibutum as active agent. Also a number of auxiliary components is a part of drug:

  • microcrystallic cellulose (Cellulosum microcrystallicum);
  • silicon dioxide colloid (Colloidal anhydrous Silica);
  • sodium glycollate starched (Sodium starch glycolate);
  • calcium stearate (Calcium stearate).

Release form

Drug is issued in the form of ploskotsilindrichesky tablets which color can vary from white to slightly yellowish. On each tablet are available risk and a facet.

Pharmacological action

Drug belongs to group of psychogogic and nootropic medicines.

The pharmacological effect which had by Phenibutum:

  • nootropic;
  • anksiolitichesky.

Pharmacodynamics and pharmacokinetics

What is Phenibutum?

In Wikipedia it is specified that Phenibutum on the structure represents phenylic derivative piperidic acid — the substance which is carrying out function of the inhibiting TsNS mediator in a human body. Also Phenibutum it is possible to consider as derivative a fenetilamin.

Substance represents white powder with crystal structure and acid taste. Powder is well dissolved in water and alcohols. The hydrogen indicator (pH) of aqueous solution of Phenibutum is ranging from 2,3 to 2,7.

Pharmacodynamics

Working as nootrop, Phenibutum exerts positive impact on the highest integrative activity of a human brain. It stimulates cerebration, cognitive functions, memory function, and also promotes increase of resistance of a brain to influence of various disturbing factors, including including extreme loadings and air hunger.

Phenibutum reduces expressiveness of effects of the serious diseases connected with craniocereberal injuries, strokes, injuries of a spinal cord, brain intoxication etc.

At the patients who had a severe craniocereberal injury against administration of drug the quantity of mitochondrions in the field of perifocal changes increases and dynamics of the power processes proceeding in a brain, processes of tissue respiration, glucose utilization by a brain, and also blood supplies improves.

Besides, drug promotes strengthening of kortiko-subcortical bonds, that is, in other words, bonds between a cerebral cortex and its subcrustal departments.

Pharmacological activity of Phenibutum is expressed in ability:

  • to exert the adjusting impact on the highest cortical functions broken owing to local damages of a brain;
  • to improve critical opportunities and to increase the level of judgments;
  • to improve cortical control of activity of subcortical zones;
  • to exert impact on the processes connected with memory function (storing and reminiscence, ability to training);
  • to increase wakefulness level, to influence a condition of the oppressed or dulled consciousness, increasing its clarity;
  • to increase the level of the general resistance of an organism to influence a stress factors;
  • to have anti-asthenic effect which is expressed in weakness reduction, elimination of symptoms of a mental and physical adynamy, slackness reduction, etc.;
  • to stimulate mental activity (drug reduces expressiveness of mental block, increases strong-willed activity, stimulates motor and speech performance, etc.);
  • to have antidepressive effect;
  • to have sedative and tranquilizing effect, reducing irritability and emotional excitability.

The stimulating influence of Phenibutum is not followed by increase of speech or motor excitement, exhaustion of functional reserves of an organism, accustoming to drug and development of dependence on it.

As well as other nootropa, means it is characterized by small toxicity, good compatibility with drugs of other farmakoterapevtichesky groups, and also lack of serious side effects and complications.

The therapeutic effect of reception of Phenibutum develops gradually within, as a rule, several weeks. For this reason drug is recommended to be accepted long courses.

Anksiolitichesky effect of drug is implemented due to decrease in excitability of the subcortical structures of a brain (including structures of a limbic complex, a thalamus and a hypothalamus) which are responsible for emotions, braking of their interaction with a cerebral cortex and also suppression of spinal reflex activity (in particular, it oppresses polisinaptichesky spinal reflexes).

Making direct impact on receptors of γ-aminobutyric acid of acid, Phenibutum facilitates GAMK-oposredovannuyu transfer of nervous impulses in TsNS. Active agent of drug possesses ability to improve a functional condition of a brain due to normalization of the exchange processes proceeding in it and improvement of cerebral circulation.

At the same time at the patient improvement of indicators of a hemodynamics (in particular, the volume and linear speed of a blood-groove increases) is noted, vascular resistance indicators decrease, microcirculation improves (including in eye tissues) and the conditions interfering the spontaneous and induced aggregation of thrombocytes are created (that in turn reduces probability of formation of blood clots at the people suffering from disturbances of blood circulation in a brain).

Besides, Phenibutum has antioxidant and anticonvulsant effect.

At treatment drug of patients of old age at the last does not note oppression of the TsNS function, decrease in a muscle tone and increase of the general slackness.

Drug reduces the oppressing effect of alcohol by TsNS.

Pharmacokinetics

Getting to an organism, Phenibutum is well absorbed and then also well distributed in its various fabrics. Substance with ease passes through GEB which represents a physiological barrier between system of blood vessels and TsNS.

About 0,1% of the accepted drug dose get to tissues of a brain. And this indicator higher for persons of young and old age.

Phenibutum is characterized by ability to be distributed evenly in a liver and kidneys. Substance biotransformation for 80-95% is carried out in liver tissues. The formed metabolism products do not possess pharmacological activity.

Cumulation of substance in an organism is not noted. Process of removal of Phenibutum of an organism begins about three hours later. And concentration of substance in tissues of a brain does not decrease. It is possible to find it in a brain on an extent of six hours.

About 5% of Phenibutum are excreted from an organism by kidneys in pure form, partially substance is removed together with bile.

Indications to use of Phenibutum

Indications to use of Phenibutum are:

  • decrease in intellectual activity;
  • decrease in emotional activity;
  • dysmnesias;
  • symptoms of an asthenic syndrome;
  • alarming frustration;
  • fears, including nightmares;
  • the increased uneasiness, concern;
  • decrease in concentration of attention;
  • dyssomnia (sleeplessness);
  • alcohol addiction, and also the psychopathological and somato-vegetative frustration arising as a result of alcoholic abstinence (in combination with other therapeutic actions);
  • Menyer's syndrome;
  • dizzinesses which reason the vestibular dysfunction caused by diseases of vascular system, injuries or infectious diseases is;
  • prevention of the motion deseases caused by a movement illness (kinetozy);
  • osteochondrosis in cervical and/or chest department of a backbone and climacteric frustration at women (drug is appointed in combination with other therapeutic actions);
  • stutter, urine incontience, hyperactivity and tics at children.

The tablets Phenibutum in combination with other disintoxication means are also used for treatment of a condition of cancellation of alcohol with a delirium (a delirious syndrome — illusory and hallucinatory stupefaction which is followed by a disorientation in time, the place and in some cases in own personality) and an alcoholic predeliriozny state.

The indication on the medicine Phenibutum is also prevention of stressful states which are quite often noted at patients before surgeries and painful diagnostic testings.

Contraindications

The summary lists the following contraindications to purpose of Phenibutum:

  • individual hypersensitivity to Phenibutum or some of the excipients which are a part of drug;
  • pregnancy;
  • lactation;
  • age till eight years;
  • acute renal failure.

With care Phenibutum is appointed to patients with pathologies of the alimentary system and erosive cankers of a gastrointestinal tract. Are shown to this category of patients in reduced doses of drug as the last is characterized by ability to irritate mucous.

Side effects

As a rule, side effects after reception of Phenibutum arise only at initial stages of therapy. Most often at patients drowsiness increases, there are nausea attacks, headaches, jumps of indicators of arterial pressure are noted.

At separate groups of patients Phenibutum provokes the following side effects:

  • irritability increase;
  • increase of level of uneasiness;
  • excitement increase;
  • dizzinesses;
  • individual allergic reactions.

Application instruction of Phenibutum (Way of reception and dosage)

The application instruction of the tablets Phenibutum specifies that drug is intended for intake by courses which duration varies ranging from one about one and a half months.

Adults are recommended to take a pill in the daily dose equal of 0,75-1,5 g. Frequency rate of receptions is equal to 3. When it is reasonable, the daily dose is allowed to be raised to 2,5 g.

The most admissible single dose of medicine for the adult patient 60 years are younger the dose equal to 0,75 g of Phenibutum is considered. People of advanced age are not recommended to accept more than 0,5 g of Phenibutum at one time.

Tablets Phenibutum: the application instruction and a dosage at various diseases

To the patients suffering from dizzinesses owing to an inflammation of an inner ear and also people with the diagnosis Menyer Fenibut's syndrome is appointed according to the following scheme: during the periods of exacerbations of a disease drug is accepted on 0,75 g three times a day within five-seven days; at reduction of expressiveness of symptoms of vestibular dysfunction the dose is reduced to 0,25-0,5 g three times a day (in such dosage drug is accepted within five-seven days); further treatment is continued within five days, accepting 0,25 g of Phenibutum of times a day.

If the disease proceeds in rather easy form, Phenibutum is recommended to accept in the daily dose equal 0,5 g, for five-seven days. The dose is divided into two receptions. Further treatment is continued within one-three weeks, accepting once a day 0,25 g of drug.

For treatment of the dizzinesses provoked by injuries or vascular diseases, drug is appointed in the daily dose equal to 0,75 g of Phenibutum. It is recommended to divide it into three receptions. Duration of a therapeutic course usually makes about two weeks.

For treatment of osteochondrosis of cervical and/or chest department of a backbone and removal of symptoms of a menopausal syndrome at women Phenibutum is appointed in combination with other therapeutic actions.

For the first two weeks it is necessary to accept drug on one tablet three times a day (the daily dose of drug makes 0,75 g). Further the number of receptions reduce to two, the dose remains former — one tablet on each reception (the daily dose of drug makes 0,5 g).

In case of moderate expressiveness of a pain syndrome at vertebralny pathology or a menopausal syndrome Phenibutum is appointed to accept in a combination with other drugs on one tablet twice a day (0,5 g a day). The recommended duration of a course of treatment — four weeks.

As well as its analogs, Phenibutum it is used in the preventive purposes for the prevention of so-called diseases of travel or, speaking in other words, a syndrome of the motion desease arising during flight by the airplane or voyage.

For prevention of a syndrome of a motion desease at a sea sickness Phenibutum is accepted disposable approximately for an hour before the planned travel or if the first symptoms of a kinetoz appeared. The dose equal of 0,25-0,5 g is considered optimum (or one-two tablets). Effect of drug has dozozavisimy character.

However at emergence of the expressed motion desease symptoms (for example, severe vomiting) ineffective is even a dose equal of 0,75-1 g.

For prevention of a motion desease at aeroembolism Phenibutum is recommended to be accepted according to the above described scheme. That is 1-2 tablets approximately for an hour before the planned travel.

The application instruction of Phenibutum for children

Drug is not intended for treatment of children more young than eight-year age.

To children aged from eight till fourteen years the daily dose of Phenibutum makes 0,75 g, that is three tablets of 0,25 g a day. It is necessary to divide it into three receptions.

In cases, when necessary, it is allowed to accept drug in the highest single dose which makes 0,3 g.

How to accept Phenibutum at the admission of the next dose?

If the patient one or several times missed reception of the next dose of drug, the course of treatment is continued according to earlier appointed dosing mode.

Overdose

Overdose by drug is followed by the following symptoms:

Treatment assumes a gastric lavage, induction of vomiting and purpose of symptomatic therapy. Drug has no specific antidote.

As Phenibutum represents low-toxic connection, only its long reception in the doses significantly exceeding therapeutic (from 7 to 14 g a day) can provoke development of hepatotoxic effects.

In particular, at the patient the quantity of eosinophils in peripheral blood increases over physiological norm, and also the steatosis (a fatty infiltration) of a liver — the chronic disease caused by accumulation in tissues of a liver of a large amount of triglycerides and which is characterized by fatty dystrophy of cells of body can develop.

Interaction

For the purpose of a mutual potentsiirovaniye of pharmacological effects Phenibutum combination with other psychotropic drugs is allowed. At the same time the dose of Phenibutum and the medicines combined with it has to be reduced.

Drug is characterized by ability to strengthen and increase duration of effect of somnolent drugs, narcotic analgetics, antipsychotic and anticonvulsant medicines.

The possibility of lengthening and strengthening of therapeutic effect of reception of antiepileptic drugs does Phenibutum by medicine of the first line in case of need of purpose of nootropic therapy to the patients sick with epilepsy.

Strengthens toxic effects and effect of alcohol. Besides, there are data on what under its influence amplifies as well action of protivoparkinsonichesky means.

Terms of sale

Drug is released without recipe.

Storage conditions

It is necessary to store Phenibutum in unavailable to children, the dry, dark place at a temperature no more than 25 °C.

Period of validity

Drug keeps the pharmacological properties within 36 months from the date of production. After this term it is impossible to use it.

Special instructions

At long reception of Phenibutum it is necessary to control change of indicators of functional activity of a liver and the characteristic of a picture of peripheral blood.

Throughout all course of treatment drug it is necessary to abstain from performance of work, interfaced to risk for health and life, and works demanding the increased concentration of attention and high speed of mental and motor reactions.

Analogs of Phenibutum

Analogs of Phenibutum are the medicines possessing action, similar to it, but differing on composition of active agents. Carry to them:

Zdravzona

  • Tablet/Belmedpreparaty/Belmedpreparata Phenibutum No. 20
  • Tablet Phenibutum No. 20 olaynfarmolaynfarm joint-stock company
  • Tabletkibelmedpreparata Phenibutum No. 10
  • Phenibutum No. 20 tabletkiozon Ltd company
  • Tablet/MEZ Phenibutum No. 20 / Moscow endocrine plant of federal state unitary enterprise

Drugstore of IFC

  • Phenibutum tbl 250 mg No. 20, Olainfarmlatviya
  • Phenibutum tbl 250 mg No. 20, Belmedpreparata (Minsk) Belarus
to show still

Apteka24

  • Noofen (Phenibutum) of a tablet 250 of mg No. 20 Olaine HFZ (Latvia)

Paniapteka

  • Noofen (Phenibutum) kaps. 250 mg No. 20 Olaine HFZ
  • Phenibutum of the tab. of 250 mg No. 20
  • Noofen (Phenibutum) kaps. 250 mg No. 20 Olaine HFZ
  • Noofen (Phenibutum) kaps. 250 mg No. 20 Olaine HFZ
  • Noofen (Phenibutum) kaps. 250 mg No. 20 Olaine HFZ

BIOSPHERE

  • Phenibutum of 250 mg No. 20 of the tab. of Belmedpreparata (Belarus)
to show still
Section: For a nervous system
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before medicine use Phenibutum surely consult with the attending physician.